BACKGROUND: The predominant strain during the 2013-2014 influenza season was 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09). This vaccine-component has remained unchanged from 2009. METHODS: The US Flu Vaccine Effectiveness Network enrolled subjects aged ≥6 months with medically attended acute respiratory illness (MAARI), including cough, with illness onset ≤7 days before enrollment. Influenza was confirmed by reverse-transcription polymerase chain reaction (RT-PCR). We determined the effectiveness of trivalent or quadrivalent inactivated influenza vaccine (IIV) among subjects ages ≥6 months and the effectiveness of quadrivalent live attenuated influenza vaccine (LAIV4) among children aged 2-17 years, using a test-negative design. The effect of prior receipt of any A(H1N1)pdm09-containing vaccine since 2009 on the effectiveness of current-season vaccine was assessed. RESULTS: We enrolled 5999 subjects; 5637 (94%) were analyzed; 18% had RT-PCR-confirmed A(H1N1)pdm09-related MAARI. Overall, the effectiveness of vaccine against A(H1N1)pdm09-related MAARI was 54% (95% confidence interval [CI], 46%-61%). Among fully vaccinated children aged 2-17 years, the effectiveness of LAIV4 was 17% (95% CI, -39% to 51%) and the effectiveness of IIV was 60% (95% CI, 36%-74%). Subjects aged ≥9 years showed significant residual protection of any prior A(H1N1)pdm09-containing vaccine dose(s) received since 2009, as did children <9 years old considered fully vaccinated by prior season. CONCLUSIONS: During 2013-2014, IIV was significantly effective against A(H1N1)pdm09. Lack of LAIV4 effectiveness in children highlights the importance of continued annual monitoring of effectiveness of influenza vaccines in the United States.
BACKGROUND: The predominant strain during the 2013-2014 influenza season was 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09). This vaccine-component has remained unchanged from 2009. METHODS: The US Flu Vaccine Effectiveness Network enrolled subjects aged ≥6 months with medically attended acute respiratory illness (MAARI), including cough, with illness onset ≤7 days before enrollment. Influenza was confirmed by reverse-transcription polymerase chain reaction (RT-PCR). We determined the effectiveness of trivalent or quadrivalent inactivated influenza vaccine (IIV) among subjects ages ≥6 months and the effectiveness of quadrivalent live attenuated influenza vaccine (LAIV4) among children aged 2-17 years, using a test-negative design. The effect of prior receipt of any A(H1N1)pdm09-containing vaccine since 2009 on the effectiveness of current-season vaccine was assessed. RESULTS: We enrolled 5999 subjects; 5637 (94%) were analyzed; 18% had RT-PCR-confirmed A(H1N1)pdm09-related MAARI. Overall, the effectiveness of vaccine against A(H1N1)pdm09-related MAARI was 54% (95% confidence interval [CI], 46%-61%). Among fully vaccinated children aged 2-17 years, the effectiveness of LAIV4 was 17% (95% CI, -39% to 51%) and the effectiveness of IIV was 60% (95% CI, 36%-74%). Subjects aged ≥9 years showed significant residual protection of any prior A(H1N1)pdm09-containing vaccine dose(s) received since 2009, as did children <9 years old considered fully vaccinated by prior season. CONCLUSIONS: During 2013-2014, IIV was significantly effective against A(H1N1)pdm09. Lack of LAIV4 effectiveness in children highlights the importance of continued annual monitoring of effectiveness of influenza vaccines in the United States.
Authors: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245
Authors: Douglas M Fleming; Pietro Crovari; Ulrich Wahn; Timo Klemola; Yechiel Schlesinger; Alexangros Langussis; Knut Øymar; Maria Luz Garcia; Alain Krygier; Herculano Costa; Ulrich Heininger; Jean-Louis Pregaldien; Sheau-Mei Cheng; Jonathan Skinner; Ahmad Razmpour; Melanie Saville; William C Gruber; Bruce Forrest Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Shai Ashkenazi; Andre Vertruyen; Javier Arístegui; Susanna Esposito; David Douglas McKeith; Timo Klemola; Jiri Biolek; Joachim Kühr; Tadeusz Bujnowski; Daniel Desgrandchamps; Sheau-Mei Cheng; Jonathan Skinner; William C Gruber; Bruce D Forrest Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Bruce D Forrest; Michael W Pride; Andrew J Dunning; Maria Rosario Z Capeding; Tawee Chotpitayasunondh; John S Tam; Ruth Rappaport; John H Eldridge; William C Gruber Journal: Clin Vaccine Immunol Date: 2008-04-30
Authors: Stephanie A Irving; James G Donahue; David K Shay; Tina L Ellis-Coyle; Edward A Belongia Journal: Vaccine Date: 2009-09-01 Impact factor: 3.641
Authors: Herve Caspard; Manjusha Gaglani; Lydia Clipper; Edward A Belongia; Huong Q McLean; Marie R Griffin; H Keipp Talbot; Katherine A Poehling; Timothy R Peters; Naomi Veney; Christopher S Ambrose Journal: Vaccine Date: 2015-11-14 Impact factor: 3.641
Authors: Marie R Griffin; Arnold S Monto; Edward A Belongia; John J Treanor; Qingxia Chen; Jufu Chen; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Gerry Lofthus; Joshua G Petrie; Jennifer K Meece; Caroline Breese Hall; John V Williams; Paul Gargiullo; LaShondra Berman; David K Shay Journal: PLoS One Date: 2011-08-12 Impact factor: 3.240
Authors: Jessie R Chung; Brendan Flannery; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Emily T Martin; Arnold S Monto; Huong Q McLean; Edward A Belongia; Manjusha Gaglani; Alicia M Fry Journal: J Infect Dis Date: 2017-07-15 Impact factor: 5.226
Authors: Kate Russell; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Brendan Flannery Journal: Vaccine Date: 2018-02-28 Impact factor: 3.641
Authors: Jay V DePasse; Mary Patricia Nowalk; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman; Shawn T Brown Journal: Hum Vaccin Immunother Date: 2019-06-18 Impact factor: 3.452
Authors: Kelly Stefano Cole; Judith M Martin; William T Horne; Chyongchiou J Lin; Mary Patricia Nowalk; John F Alcorn; Richard K Zimmerman Journal: Vaccine Date: 2017-11-11 Impact factor: 3.641
Authors: Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia Journal: JAMA Netw Open Date: 2018-10-05
Authors: Samantha M Harrison; Melissa Y Wei; Lois E Lamerato; Joshua G Petrie; Emily Toth Martin Journal: Vaccine Date: 2018-05-07 Impact factor: 3.641